This program will include a discussion of data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal Immunotherapy in Gastrointestinal ID: 749206
Download Presentation The PPT/PDF document "Advances in Gastrointestinal Cancers" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Advances in Gastrointestinal CancersSlide2
This program will include a discussion of data that were presented in abstract form.
These data should be considered preliminary until published in a
peer-reviewed journal.Slide3
Immunotherapy in Gastrointestinal MalignanciesSlide4
dMMR and PD-1 BlockadeSlide5
dMMR and PD-1 Blockade (cont)Slide6
dMMR and PD-1 Blockade (cont)Slide7
Immunotherapy in Hepatocellular CarcinomaSlide8
Nivolumab Monotherapy in HCCCheckMate-040Slide9
CheckMate-040Subset AnalysisSlide10
Pembrolizumab Monotherapy in HCCKEYNOTE-224Slide11
Durvalumab Monotherapy in HCCSlide12
Dual Checkpoint Inhibitor Therapy in HCCSlide13
Combined VEGF Inhibition and PD-1 Inhibition in HCCSlide14
Ongoing Trials and Future Directions Slide15
Immunotherapy in Gastroesophageal CancerSlide16
Pembrolizumab Monotherapy in Gastric/Gastroesophageal CancerSlide17
Nivolumab Monotherapy in Gastric and GE Junction CancerSlide18
Avelumab Monotherapy in Advanced Gastric or GE Junction CancerSlide19
Pembrolizumab Monotherapy in Gastric and GE Junction CancerSlide20
Dual Checkpoint Inhibitors in Gastric and GE
Junction Cancers: Nivolumab + IpilimumabSlide21
Dual Checkpoint Inhibitors in Gastric
and GE Junction Cancers: Durvalumab + TremelimumabSlide22
Combination VEGFR-2 and PD-1 Inhibition in the Second Line Management of Gastric or GE Junction Adenocarcinoma Slide23
Ongoing Trials and Future DirectionsSlide24
Immunotherapy in Pancreatic AdenocarcinomaSlide25
Immunotherapy in Pancreatic CancerSlide26
Dual Checkpoint Inhibitors in Pancreatic CancerSlide27
Chemotherapy in Combination With Checkpoint InhibitorsSlide28
Other Immunomodulating AgentsIDO-1 InhibitorsSlide29
Other Immunomodulating Agents: CSF1R BlockadeSlide30
Pancreatic ImmunotherapyOngoing trialsSlide31
Concluding RemarksSlide32